BIONOMICS LIMITED

Press Releases Bionomics Limited

Equities

BNOX

US09063M2052

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-20 EDT			5-day change	1st Jan Change
0.9167 ^USD	+1.58%		-0.56%	-38.06%

03-21	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI
03-15	Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	06:30am	AQ
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	03-21	AQ
Bionomics : Notes to the Consolidated Financial Statements - Form 6-K	03-15	PU
Bionomics to Present at the 2024 BIO CEO & Investor Conference	02-22	AQ
Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVL	01-29	AQ
Bionomics Provides a Review of 2023 and of 2024 Plans	01-22	AQ
Bionomics to Present at Biotech Showcase™ 2024	01-05	AQ
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting	12-06	AQ
Bionomics : Results of Annual General Meeting - Form 6-K	11-30	PU
Bionomics : • Operations Presentation	11-30	PU
Bionomics : Announces Retirement of Board Member - Form 6-K	11-28	PU
Bionomics : Announces Retirement of Board Member	11-27	PU
Bionomics : Notice of Annual General Meeting Explanatory Statement and Proxy Form - Form 6-K	11-03	PU
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder	23-10-16	AQ
Bionomics : Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder - Form 6-K	23-10-16	PU
Bionomics : Statutory Accounts - Form 6-K	23-09-29	PU
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)	23-09-28	AQ
Bionomics Limited participated in the H.C Wainwright BioConnect Conference	22-01-12	PR
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder	22-01-03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW